2 Results for "

PRLR ADC antibody

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "PRLR ADC antibody" in MCE Product Catalog:

Rolinsatamab talirine
Rolinsatamab talirine
0 Images
Cat. No.: HY-P99881
CAS No.: 2095467-44-8
Synonyms: ABBV 176

Target:  

Antibody-Drug Conjugates (ADCs)

Research Areas:  

Cancer

Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .
loading...
    loading...
View All Sizes
REGN2878
REGN2878
0 Images
Cat. No.: HY-P992449
Synonyms: PRLR ADC antibody

Target:  

ADC Antibodies

Research Areas:  

Cancer

REGN2878 (PRLR ADC antibody) is a monoclonal antibody targeting the prolactin receptor (PRLR) and can block prolactin‑mediated activation of PRLR. REGN2878 exhibits an equilibrium dissociation constant (KD) of 1.05 nM and an IC50 of 0.344 nM for human PRLR. REGN2878 can be rapidly internalized and degraded in lysosomes by PRLR‑positive tumor cells, showing antigen‑specific binding and targeted enrichment properties. REGN2878 derivatives can be used as an immunoPET agent for antigen‑specific imaging of PRLR‑related tumors, and can also serve as a component of ADCs to exert anti‑tumor activity in breast cancer xenograft models. REGN2878 can be used in the research of breast cancer and prostate cancer. Isotype Comparison HY-P99001 .
loading...
    loading...
View All Sizes
Assay Types